Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?

Abstract

Doctors plan to prescribe bevacizumab despite legal threats from drug companies, and against GMC and NICE guidance. Responses to the policy and new legal rulings hint at a turning point in a long-running battle in which £0.5bn potential NHS savings are at stake, reports Deborah Cohen

CCGs face legal threat for offering off-label drug for wet AMD

“…The veracity of these concerns have been disputed. 4 A Bayer spokesperson told The BMJ, "We are determined to work with the appropriate authorities to ensure a resolution that is lawful and protects the interests and wellbeing of patients." …”